My opinion is all guess. I am a bit skeptical the data will be fantastic. Its phase 1 with very sick patients and the patient numbers trialing the treatments are low. But I would be suprised if the data wasnt good and justifying moving up to phase 2. They need a commercial deal to finance further research.
Its looking a bit bleak but I will hold for the results. There could easily be a suprise. If IMU fizzles out over the next 12 months it would be quite a humiliation for its directors and team. A humiliation for me to but a very good learning experience. I think it is still a buy at these prices though speculative.
IMU Price at posting:
3.7¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)